TriMaster: randomised double-blind crossover trial of a DPP4-inhibitor, SGLT2-inhibitor and thiazolidinedione to evaluate differential glycaemic response to therapy based on obesity and renal function (2022)

First Author: Hattersley A

Attributed to: Developing a decision support tool to enable precision treatment of type 2 diabetes funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.21203/rs.3.rs-2132634/v1

Publication URI: http://dx.doi.org/10.21203/rs.3.rs-2132634/v1

Type: Preprint